ARTV Artiva Biotherapeutics
- 10.600
- -0.070-0.66%
Artiva Biotherapeutics News
H.C. Wainwright Initiates Artiva Biotherapeutics(ARTV.US) With Buy Rating, Announces Target Price $20
TD Cowen Maintains Artiva Biotherapeutics(ARTV.US) With Buy Rating
Needham Maintains Artiva Biotherapeutics(ARTV.US) With Buy Rating, Maintains Target Price $23
Artiva Biotherapeutics Analyst Ratings
Needham Reiterates Buy on Artiva Biotherapeutics, Maintains $23 Price Target
Artiva Biotherapeutics, Inc.: Strong Buy Rating Supported by Robust Autoimmune Pipeline and Financial Stability
TD Cowen Maintains Artiva Biotherapeutics(ARTV.US) With Buy Rating
Artiva Biotherapeutics, Inc. (ARTV) Receives a Buy From TD Cowen
TD Cowen Maintains Artiva Biotherapeutics(ARTV.US) With Buy Rating
Artiva Biotherapeutics Analyst Ratings
Needham Reiterates Buy on Artiva Biotherapeutics, Maintains $23 Price Target
Wedbush Maintains Artiva Biotherapeutics(ARTV.US) With Buy Rating, Maintains Target Price $18
Artiva Biotherapeutics, Inc. (ARTV) Receives a Buy From Wedbush
Needham Maintains Artiva Biotherapeutics(ARTV.US) With Buy Rating, Maintains Target Price $23
Buy Rating Affirmed for Artiva Biotherapeutics Amidst Clinical Advancements and Strong Financials
A Quick Look at Today's Ratings for Artiva Biotherapeutics(ARTV.US), With a Forecast Between $18 to $23
A Quick Look at Today's Ratings for Artiva Biotherapeutics(ARTV.US), With a Forecast Between $18 to $23
Artiva Biotherapeutics Price Target Announced at $23.00/Share by Cantor Fitzgerald
Artiva Biotherapeutics Analyst Ratings
Jefferies Initiates Artiva Biotherapeutics at Buy With $21 Price Target
No Data
